pSivida Corp. Announces First Quarter 2010 Financial Results Release Date and Conference Call Information
The conference call may be accessed by dialing (888) 713-4215 from the
U.S. and
A replay of the call will be available approximately two hours following
the end of the call through
The conference call will be available via the Internet at www.psivida.com and will also be distributed through the Thomson StreetEvents Network. Individual investors can listen to the call via www.earnings.com and Institutional investors can access the call via www.streetevents.com. The call will be archived and accessible on the Web site for approximately 30 days.
Listeners are encouraged to login at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software.
About
pSivida is a world leader in the development of tiny, sustained release,
drug delivery products that are administered by implantation, injection
or insertion. pSivida’s lead development product delivers fluocinolone
acetonide (FA) for the treatment of diabetic macular edema (DME). This
product candidate, formerly known as Medidur™ FA for DME, is licensed to
Alimera, which is conducting fully recruited Phase III clinical trials
and intends to commercialize the product under the name Iluvien®.
pSivida also has two products approved by the
pSivida owns the rights to develop and commercialize a modified form of silicon known as BioSilicon™, which has potential therapeutic applications. The most advanced BioSilicon product candidate, BrachySil™, delivers a therapeutic P32, a radioactive form of phosphorus used to treat cancer, directly to solid tumors. pSivida has completed an initial safety clinical trial and a follow-on dose-ranging clinical trial of BrachySil for the treatment of pancreatic cancer.
pSivida’s intellectual property portfolio consists of 62 patent
families, over 100 granted patents, including patents accepted for
issuance, and over 200 patent applications. pSivida conducts its
operations from
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. The following are
some of the factors that could cause actual results to differ materially
from the forward-looking statements: continued losses and lack of
profitability; inability to derive revenue from Retisert; impairment of
intangibles; fluctuations in the fair values of certain outstanding
warrants; fluctuations in operating results; inability to raise capital;
termination of license agreements; inability to obtain regulatory
approvals for products; inability to obtain partners to develop and
market products; competition; insufficient third-party reimbursement for
products; inability to protect intellectual property or infringement of
others’ intellectual property; failure to retain key personnel;
consolidation in the pharmaceutical and biotechnology industries;
failure to comply with laws and regulations; manufacturing problems;
risks and costs of international business operations; volatility of
stock price; possible dilution through exercise of outstanding warrants
and stock options or through future stock issuances; possible influence
by Pfizer; payment of registration penalties; nonpayment of dividends;
and other factors that may be described in our filings with the
Source:
In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak,
President
312-943-1123
bjedynak@janispr.com
or
In
Australia:
pSivida Corp.
Brian Leedman, Vice President,
Investor Relations
+61 8 9227 8327
brianl@psivida.com
